Dorsey & Whitney Trust CO LLC Raises Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Dorsey & Whitney Trust CO LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.7% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,700 shares of the pharmaceutical company’s stock after purchasing an additional 146 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Vertex Pharmaceuticals were worth $1,309,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Clal Insurance Enterprises Holdings Ltd grew its holdings in Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Mascagni Wealth Management Inc. bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at about $31,000. SJS Investment Consulting Inc. lifted its holdings in Vertex Pharmaceuticals by 46.2% during the 1st quarter. SJS Investment Consulting Inc. now owns 95 shares of the pharmaceutical company’s stock worth $46,000 after buying an additional 30 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth approximately $46,000. Finally, Stone House Investment Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $48,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright reduced their price objective on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research note on Tuesday, August 5th. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 23rd. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price for the company in a research note on Wednesday, August 6th. Wall Street Zen raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 9th. Finally, Truist Financial set a $490.00 price target on Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and thirteen have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $497.10.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock opened at $394.36 on Thursday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The company has a market capitalization of $101.11 billion, a P/E ratio of 28.19 and a beta of 0.44. The business’s fifty day moving average price is $441.45 and its two-hundred day moving average price is $462.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. The company had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the company earned ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.